


**Class A: ETAHX | Class C: ETCHX | Class I: ETIHX | Class N: ETNHX**

The Eventide Healthcare & Life Sciences Fund seeks to provide long-term capital appreciation by investing in securities of healthcare and life sciences companies. The fund invests in companies that we believe demonstrate values and practices that are ethical, sustainable, and provide a good investment opportunity. The fund also invests in securities with significant near-term appreciation potential. Under normal market conditions, the Fund will invest at least 80 percent of its net assets in equity and equity-related securities of companies in the healthcare and life sciences sectors.

### TOP HOLDINGS\*

<b>Supernus Pharmaceuticals Inc (3.35%)</b> Pioneering new medicines in neurology and psychiatry	<b>Celgene Corp (2.71%)</b> Discovery, development and commercialization of life-changing cancer therapies
<b>Bluebird Bio Inc (3.20%)</b> Leader in gene therapy, cancer immunotherapy and gene editing	<b>Veracyte Inc (2.47%)</b> Develops molecular tests for oncology
<b>Blueprint Medicines Corp (3.07%)</b> A new generation of kinase therapies for genomic diseases	<b>Collegium Pharmaceutical Inc (2.43%)</b> Abuse-deterrent treatments for chronic pain
<b>Loxo Oncology Inc (2.91%)</b> Treating cancer at the genomic level with targeted chemical therapies	<b>Xencor Inc (2.38%)</b> Engineering antibody immune functions to make better drugs
<b>Kite Pharma Inc (2.91%)</b> Leader in immunology using engineered T cell therapy	<b>Spark Therapeutics Inc (2.31%)</b> Innovating gene therapies for inherited diseases

### Growth of \$10,000<sup>†‡</sup>



### Fund Returns<sup>‡</sup>

	3 month	1-year	3-year <sup>††</sup>	31 Mar 2017
<i>Eventide Healthcare &amp; Life Sciences Fund</i>				<i>Since Inception<sup>††</sup></i>
Class N	12.93%	24.12%	8.83%	21.38%
Class A without load	12.86%	24.02%	8.77%	21.28%
Class A with 5.75% load	6.40%	16.92%	6.64%	19.60%
Class C	12.68%	23.13%	7.98%	20.40%
Class I	12.93%	24.30%	9.04%	21.59%
<i>Benchmarks</i>				
Healthcare Blended Index**	9.56%	20.77%	15.77%	22.46%
S&P 500 Total Return Index**	6.07%	17.17%	10.37%	15.14%

\* Based on percentage of net assets. Holdings can change at any time and should not be considered investment advice.

† These charts compare the Eventide Healthcare & Life Sciences Fund Class N's performance to index performance over the periods shown. Performance will differ for other fund classes, based upon fees and commissions. The Growth of \$10,000 Chart assumes the Fund's inception date of 27 December 2012 for the indices.

‡ The returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or on the redemption of Fund shares. Because of ongoing market volatility, Fund performance may be subject to substantial short-term changes.

\*\* The S&P 500 is an index created by Standard & Poor's of American stocks with the largest market capitalization. It is not an investment product available for purchase. The Healthcare Blended Index is composed of equal parts of the S&P 400 Healthcare Index and the S&P 600 Healthcare Index from Fund inception on 27 December, 2012. The volatility of the indices may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as the indices listed.

†† Performance figures for periods greater than 1 year are annualized. Annualized since inception returns assume an inception date of 27 December 2012.

Performance is historic and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index and unmanaged index returns do not reflect any fees, expenses or sales charges. To obtain the most recent month-end performance information and a current Eventide Healthcare & Life Sciences Fund prospectus please call the fund, toll free at 1-877-771-EVEN (3836).

Class A: ETAHX | Class C: ETCHX | Class I: ETIHX | Class N: ETNHX

**OVERVIEW**

Fund	Nasdaq	Maximum Sales Charge	12b-1 Fees	Total Expenses	Minimum Investment
Class A	ETAHX	Front-end*: 5.75%	0.25%	1.60%	\$1,000 or \$100 with AIP
Class C	ETCHX	None	1.00%	2.35%	\$1,000 or \$100 with AIP
Class I	ETIHX	None	0.00%	1.35%	\$100,000
Class N	ETNHX	None	0.20%	1.55%	\$1,000 or \$100 with AIP


Inception Date: 12/27/2012  
 Net assets: \$346 million  
 Redemption Fee: 1.00% if held for less than 180 days.

**MANAGERS**

**Dr. Finny Kuruvilla** has a unique background in healthcare, statistics, and investing. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master's degree in Electrical Engineering and Computer Science from MIT, and a bachelor's degree from Caltech in Chemistry. He completed his residency and fellowship at the Brigham & Women's Hospital and Children's Hospital Boston where he cared for adult and pediatric patients suffering from a variety of hematologic, oncologic, and autoimmune disorders. Subsequently, he was a research fellow at MIT where he designed and implemented statistical algorithms involving logistic regression and pseudo-Bayesian expectation maximization. As an avid proponent of values-based investing, Dr. Kuruvilla has developed standards for selecting ethical companies at the outset of the stock selection process.




**Portfolio Composition**<sup>†</sup> % of portfolio



Equity market capitalization: \$8.49B average, \$1.09B median

**Industry Allocation**<sup>‡</sup> % of portfolio



**Market Risk**<sup>\*\*</sup>

	Std. Dev.	Beta	Alpha	R-Squared
3 Year (Annualized)	31.35%	1.89	-5.87%	39.41%
5 Year (Annualized)	-	-	-	-
Inception (Annualized) <sup>††</sup>	28.58%	1.49	2.06%	28.46%

\* Class A is also subject to a maximum deferred sales charge of 1.00%. This and other expenses that apply to a continued investment in the Fund are described in the Fund's prospectus.

† Companies valued at greater than \$10 billion are Large Cap; those at less than \$1 billion are Small Cap. Portfolio Composition is subject to change at any time, and should not be considered investment advice.

‡ Industry Allocation is subject to change at any time, and should not be considered investment advice.

\*\* Source: Zephyr StyleADVISOR, with Fund returns supplied to Zephyr by Morningstar, Inc.

Standard deviation of return measures the average deviations of a return series from its mean. StyleADVISOR calculates standard deviation as the square root of the squared differences of each monthly return from the mean monthly return over the specified period. Beta is a measure of systematic risk, or the sensitivity of ETNHX to movements in the S&P 500 Index (Index). StyleADVISOR defines Beta as the covariance of ETNHX and Index divided by the variance of the Index. Alpha is the mean of the excess return of ETNHX over beta times the Index. The R-Squared (R2) of ETNHX versus the Index is a measure of how closely related the variance of ETNHX returns and the variance of the Index returns are.

StyleADVISOR calculates R2 by squaring the correlation of monthly returns between ETNHX and the Index over the specified period.

†† Annualized since inception market risk details assume inception date of 1 January 2013 and not Fund's actual inception date of 27 December 2012, as only full month data is included in the market risk calculations.

**Mutual Funds involve risk including the possible loss of principal.**

**Past performance does not guarantee future results.** The Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The Fund's ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The Fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The Fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks. Because of ongoing market volatility, Fund performance may be subject to substantial short-term changes.

Investors should consider the Fund's objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about the Eventide Healthcare & Life Sciences Fund can be found in the fund's prospectus, which can be obtained at [www.eventidefunds.com](http://www.eventidefunds.com) or by calling 877-771-EVEN (3836). Please read the prospectus carefully before investing. The Fund is distributed by Northern Lights Distributors, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.